Kestra Medical Secures $200M Loan Facility, Reports FY26 Results and $137M FY27 Revenue Guidance
KMTS sits 82% above its 52-week low of $13.25.
Summary
Kestra Medical refinanced its debt with a $200M Pharmakon term loan, drew $75M, and reported FY26 revenue of $95.1M with FY27 guidance of $137M. The new facility improves liquidity but comes with high interest costs and restrictive covenants.
Key Events · Financing and Capital Events · KMTS
-
New $200M Senior Secured Term Loan
Entered into a five-year loan agreement with Pharmakon-managed funds, providing up to $200M across four tranches. Tranche A ($75M) was funded immediately, with net proceeds of ~$20M after repaying the prior Perceptive Credit facility and fees.
-
FY26 Revenue Up 59% to $95.1M
Revenue grew to $95.1M in FY26, driven by higher ASSURE system prescriptions (20,720, up 57%) and improved gross margin to 51.4% from 40.5%.
-
FY27 Revenue Guidance of $137M
Management guided for $137M in FY27 revenue, representing 44% growth, supported by commercial expansion and market share gains.
-
High-Cost Debt with Restrictive Covenants
The term loan carries interest at SOFR + 5.50% (floor 3.25%), a 1.75% funding fee, and make-whole prepayment penalties. The company must maintain $20M minimum liquidity and faces customary restrictive covenants.
Analysis · KMTS · Industrial Applications And Services
Kestra Medical replaced its existing debt with a new $200 million senior secured term loan from Pharmakon-managed funds, immediately drawing $75 million. Net proceeds were only about $20 million after repaying the prior lender and covering fees, but the facility provides committed future tranches tied to revenue milestones. The company also reported fiscal 2026 revenue of $95.1 million (up 59%) and guided for $137 million in FY27, a 44% increase. While the refinancing strengthens the balance sheet and extends maturity to 2031, the high interest rate (SOFR + 5.50% with a 3.25% floor) and make-whole prepayment penalties reflect the cost of capital for a company still burning cash — FY26 net loss was $131.6 million. The $262.2 million cash position and the new debt provide runway, but the combination of a dilutive prior equity offering, material weaknesses in controls, and ongoing insider selling warrants caution.
At the time of this filing, KMTS was trading at $24.18 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $13.25 to $30.00. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.